Psoralen Plus Long-Wave UV-A (PUVA) and Bexarotene Therapy
An Effective and Synergistic Combined Adjunct to Therapy for Patients With Advanced Cutaneous T-Cell Lymphoma
Karen S. McGinnis, MD;
Michael Shapiro, MD;
Carmela C. Vittorio, MD;
Alain H. Rook, MD;
Jacqueline M. Junkins-Hopkins, MD
Arch Dermatol. 2003;139:771-775.
Background Multimodality biological response–modifier therapy that includes photopheresis, interferon, and bexarotene is the standard of care in our institution for advanced cutaneous T-cell lymphoma with peripheral blood involvement. We added psoralen plus long-wave UV-A (PUVA) to this regimen in 5 patients with Sézary syndrome.
Observations All patients responded with decreased Sézary counts, resolution of lymphadenopathy, and clearing of skin disease after the addition of PUVA. Adverse effects were well tolerated and managed via close clinical and laboratory follow-up.
Conclusions The addition of PUVA to a multimodality immunomodulatory regimen in patients with Sézary syndrome can result in rapid and sustained remission of both skin and blood-borne disease. Further in vitro and in vivo studies are needed.
From the Department of Dermatology, University of Pennsylvania, Philadelphia. The authors have no relevant financial interest in this article.
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Fetal Hemoglobin Inducers from the Natural World: A Novel Approach for Identification of Drugs for the Treatment of -Thalassemia and Sickle-Cell Anemia
Bianchi et al.
Evid Based Complement Alternat Med 2007;0:nem139v1-nem139.
ABSTRACT
| FULL TEXT
Analysis of p53 Tumor Suppressor Gene, H-ras Protooncogene and Proliferating Cell Nuclear Antigen (PCNA) in Squamous Cell Carcinomas of HRA/Skh Mice Following Exposure to 8-Methoxypsoralen (8-MOP) and UVA Radiation (PUVA Therapy)
Lambertini et al.
Toxicol Pathol 2005;33:292-299.
ABSTRACT
|
